1. Home
  2. DFDV vs RIGL Comparison

DFDV vs RIGL Comparison

Compare DFDV & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DFDV
  • RIGL
  • Stock Information
  • Founded
  • DFDV 2018
  • RIGL 1996
  • Country
  • DFDV United States
  • RIGL United States
  • Employees
  • DFDV N/A
  • RIGL N/A
  • Industry
  • DFDV Finance: Consumer Services
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • DFDV Finance
  • RIGL Health Care
  • Exchange
  • DFDV Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • DFDV 330.2M
  • RIGL 335.5M
  • IPO Year
  • DFDV N/A
  • RIGL 2000
  • Fundamental
  • Price
  • DFDV $16.02
  • RIGL $38.85
  • Analyst Decision
  • DFDV Buy
  • RIGL Buy
  • Analyst Count
  • DFDV 1
  • RIGL 5
  • Target Price
  • DFDV $45.00
  • RIGL $38.20
  • AVG Volume (30 Days)
  • DFDV 3.5M
  • RIGL 995.6K
  • Earning Date
  • DFDV 08-12-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • DFDV N/A
  • RIGL N/A
  • EPS Growth
  • DFDV N/A
  • RIGL N/A
  • EPS
  • DFDV 1.17
  • RIGL 5.43
  • Revenue
  • DFDV $3,520,660.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • DFDV $70.03
  • RIGL $59.93
  • Revenue Next Year
  • DFDV $142.86
  • RIGL N/A
  • P/E Ratio
  • DFDV $13.67
  • RIGL $7.15
  • Revenue Growth
  • DFDV 97.13
  • RIGL 105.62
  • 52 Week Low
  • DFDV $0.49
  • RIGL $12.66
  • 52 Week High
  • DFDV $53.88
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • DFDV 46.25
  • RIGL 68.57
  • Support Level
  • DFDV $15.23
  • RIGL $39.00
  • Resistance Level
  • DFDV $20.30
  • RIGL $42.08
  • Average True Range (ATR)
  • DFDV 2.30
  • RIGL 2.32
  • MACD
  • DFDV 0.08
  • RIGL -0.37
  • Stochastic Oscillator
  • DFDV 19.72
  • RIGL 53.26

About DFDV DeFi Development Corp. Common Stock

DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: